PBM
APLT

Propel Bio Management’s Applied Therapeutics APLT Stock Holding History

Propel Bio Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,285,420
Closed -$6.83M – 22
2025
Q3 		$6.83M Hold
11,285,420
– – 6.83% 5
2025
Q2 		$3.51M Hold
11,285,420
– – 4.26% 6
2025
Q1 		$5.52M Buy
11,285,420
+1,670,000
+17% +$983K 6.41% 6
2024
Q4 		$8.23M Buy
9,615,420
+3,047,562
+46% +$19.1M 8.18% 5
2024
Q3 		$55.8M Hold
6,567,858
– – 32.38% 1
2024
Q2 		$30.7M Buy
6,567,858
+455,952
+7% +$2.16M 19.89% 1
2024
Q1 		$41.6M Buy
6,111,906
+736,924
+14% +$3.31M 24.19% 1
2023
Q4 		$18M Buy
+5,374,982
New +$13.4M 14.93% 2

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Propel Bio Management's APLT Position: Q4 2025 in Review

Propel Bio Management sold out of Applied Therapeutics (APLT) in Q4 2025, closing a stake of 11,285,420 shares — an estimated $6.83M sold.

Propel Bio Management first reported a position in APLT in Q4 2023 and held it in 8 quarters. The position peaked at $55.8M in Q3 2024. 52 funds tracked by Wall St. Rank hold APLT as of Q4 2025.

  • Propel Bio Management reported no remaining Applied Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Propel Bio Management sold 11,285,420 Applied Therapeutics shares in Q4 2025, an estimated $6.83M.
  • Propel Bio Management first reported a position in Applied Therapeutics in Q4 2023 and held it in 8 quarters.
  • Propel Bio Management's Applied Therapeutics position peaked at $55.8M in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2025.

Based on Propel Bio Management's 13F filing for Q4 2025, filed 11 Feb 2026.